Steven St. Peter
Steven St. Peter joined the T1D Fund in November 2019. From 2012 until 2019, Steven was Founder, President and Chief Executive Officer of Aratana Therapeutics, Inc. (NASDAQ: PETX), an animal health company focused on the licensing, development and commercialization of innovative therapeutics.
Steven was previously a Managing Director at MPM Capital in Boston where his investment scope included both venture and buyout transactions across the pharmaceutical and medical technology industries. His investment experience also includes positions at Apax Partners and The Carlyle Group. Over the past decades, Steven has founded, invested in and/or been involved with several life sciences companies including Align Technologies (NASDAQ: ALGN), Medpointe, ESP Pharma, SkinMedica, Omrix (NASDAQ: OMRI), Pharmathene (NYSE: PIP), Xanodyne, Syndax (NASDAQ: SNDX), EKR Therapeutics, Proteon (NASDAQ: PRTO), Rhythm (NASDAQ:RYTM) and others. Steven has served on the Executive Committee & Board of Directors of the New England Venture Capital Association and he has been active in a variety of other professional organizations.
Previously, Steven was Assistant Clinical Professor of Medicine at Columbia University. He received his M.D. from Washington University and completed his residency and fellowship at the Hospital of the University of Pennsylvania. He also holds an M.B.A. in Finance from the Wharton School of the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas.